Aquestive has resubmitted its needle-free epinephrine film after an FDA rejection over usability, not efficacy. This FAQ covers what changed.
News|Articles|December 26, 2025
Allergy in 2025: Year in Review
Author(s)Chelsie Derman
Fact checked by: Tim Smith
Significant advancements in allergy treatments emerge in 2025, including 4 FDA approved treatments for hereditary angioedema.
Advertisement
Advertisement
The past year saw significant progress in
Related to this article
The resubmission follows an FDA Complete Response Letter and cites human factors data showing pouch-opening time fell from 17 to 3 seconds.
In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.
Jim Blando, PhD, of Old Dominion University, explains why allergic patients' lung function dropped most 1 year after wildfire smoke exposure.
New research links wildfire smoke to lasting respiratory decline and skin flares, months after exposure ends.
What lonvo-z is, how it works, and what a Priority Review designation means for the HAE gene-editing therapy.
In this Q&A, Alysse Wurcel, MD, translates qualitative barriers into 8 concrete tactics healthcare practices can use to expand penicillin allergy delabeling.
A multi-site qualitative study identifies communication, language, and access barriers standing in the way of removing incorrect penicillin allergy labels.
Advertisement
Advertisement